MBX
MBX Biosciences Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2024-09-13
$60.89
-0.04 (-0.07%)
last quote
Want the full multi-source brief on MBX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$60.89
High
$62.45
Low
$58.84
Previous close
$60.93
Fundamentals
Market cap
$3.23B
P/E (TTM)
—
P/S (TTM)
—
P/B
3.84x
Gross margin
—
Operating margin
—
Net margin
—
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-26.01%
52W high
$72.64
52W low
$9.63
Beta
1.46x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-04in 61 days
Q3 2026EPS est $-0.88
Recent SEC filings
CIK 1776111filing-language history →
Recent news
2026-08-27 → 2026-09-03
SeekingAlpha · 5d
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. Click for more.
Benzinga · 7d
MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year clinical benefitGlobal registrational trial to enroll approximately 160 adults with HP to support
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial